Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Ming Shyen Yen, Jen Ruei Chen, Peng Hui Wang, Kuo Chang Wen, Yi Jen Chen, Heung Tat Ng, Yen Hou Chang, Yi Chang, Hsiang Tai Chao, Kuan Chong Chao, Chi Mu Chuang, Chi Hong Ho, Huann Cheng Horng, Chen Yu Huang, Ling Yu Jiang, Chia Hao Liu, Hsin Yang Li, Pi Lin Sun, Hua Hsi Wu, Fong Yuan JuChih Ping Tsai, Wen Hsun Chang, Yen Mei Hsu, Shu Yun Huang, Na Rong Lee, Chih Yao Chen, Wen Chun Chang, Chii Hou Chen, Ruey Jian Chen, Song Nan Chow, Yih Ron Lien, Bor Ching Sheu, Pao Ling Torng, Lin Hung Wei, Men Luh Yen, Wen Ling Lee, Kuan Chin Wang, Chih Long Chang, Chih Ping Chen, Tze Chien Chen, Jian Pei Huang, Ming Chao Huang, Yeou Lih Wang, Cheng Chang Chang, Jah Yao Liu, Her Young Su, Yu Chi Wang, Mu Hsien Yu, Wei Min Liu, Hung Cheng Lai, the Taiwan Association of Gynecology Systematic Review Group, Ching-Hui Chen

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

Original languageEnglish
Pages (from-to)625-634
Number of pages10
JournalTaiwanese Journal of Obstetrics and Gynecology
Volume55
Issue number5
DOIs
Publication statusPublished - Oct 1 2016

Keywords

  • targeted therapy
  • uterine endometrial stromal sarcoma
  • uterine leiomyosarcoma
  • uterine sarcoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review'. Together they form a unique fingerprint.

  • Cite this

    Yen, M. S., Chen, J. R., Wang, P. H., Wen, K. C., Chen, Y. J., Ng, H. T., Chang, Y. H., Chang, Y., Chao, H. T., Chao, K. C., Chuang, C. M., Ho, C. H., Horng, H. C., Huang, C. Y., Jiang, L. Y., Liu, C. H., Li, H. Y., Sun, P. L., Wu, H. H., ... Chen, C-H. (2016). Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. Taiwanese Journal of Obstetrics and Gynecology, 55(5), 625-634. https://doi.org/10.1016/j.tjog.2016.07.001